Atrium Therapeutics, Inc. (RNA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 12, 2026
Current Price
$12.75
Price Target
$25.00
Target Range
$25.00 — $25.00
Analyst Rating
Hold
Forward P/E—
Trailing P/E-2.8x
Forward PEG—
Implied Growth+77.3%
Median Target$25.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$25
+96.1%
Consensus
$25
+96.1%
Bull Case
$25
+96.1%
RNA Price Target Analysis
Updated June 16, 2026As of June 16, 2026, Atrium Therapeutics, Inc. (RNA) has a Wall Street consensus price target of $25.00, based on estimates from 16 covering analysts. With the stock currently trading at $12.75, this represents a potential upside of +96.1%. The company has a market capitalization of $218M.
Analyst price targets range from a low of $25.00 to a high of $25.00, representing a 0% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, RNA trades at a trailing P/E of -2.8x. Analysts expect EPS to grow +77.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+54.4%
Avg Forward P/E23.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SRPTSarepta Therapeutics, Inc. | $1.7B | $15.77 | $25.14 | +59.4% | Buy | 4.5x | 54 |
 MDWDMediWound Ltd. | $152M | $13.95 | $27.00 | +93.5% | Buy | — | 13 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.38 | $48.36 | +90.5% | Buy | — | 33 |
 BMRNBioMarin Pharmaceutical Inc. | $10.7B | $55.65 | $89.93 | +61.6% | Buy | 11.3x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $38.4B | $287.80 | $445.67 | +54.9% | Buy | 38.4x | 52 |
 IONSIonis Pharmaceuticals, Inc. | $12.2B | $73.96 | $107.27 | +45.0% | Buy | — | 32 |
 ARWRArrowhead Pharmaceuticals, Inc. | $10.9B | $77.15 | $84.00 | +8.9% | Buy | — | 20 |
 NTLAIntellia Therapeutics, Inc. | $1.7B | $14.92 | $26.29 | +76.2% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.2B | $31.12 | $48.00 | +54.2% | Buy | — | 27 |
Upside Potential Comparison
MDWDRARENTLABMRNSRPTALNYBEAMIONSWhat if you invested $1,000 in RNA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in RNA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs RNA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationRNA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowRNA — Frequently Asked Questions
Quick answers to the most common questions about buying RNA stock.
What is the RNA stock price target for 2026?
The consensus Wall Street price target for RNA is $25, representing 96.1% upside from the current price of $12.75. With 16 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is RNA a buy, sell, or hold?
RNA has a consensus rating of "Hold" based on 16 Wall Street analysts. The rating breakdown is mixed, with 9 Hold ratings making up the largest segment. The consensus 12-month price target of $25 implies 96.1% upside from current levels.
Is RNA stock overvalued or undervalued?
RNA's current price is $12.75 with a consensus target of $25 (96.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can RNA stock go?
The most bullish Wall Street analyst has a price target of $25 for RNA, while the most conservative target is $25. The consensus of $25 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RNA stock?
RNA is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 9 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RNA stock forecast?
The 12-month RNA stock forecast based on 16 Wall Street analysts shows a consensus price target of $25, with estimates ranging from $25 (bear case) to $25 (bull case). The median consensus rating is "Hold".
Should I buy RNA stock?
Wall Street analysts are very optimistic on RNA, with a "Hold" consensus rating and $25 price target (96.1% upside). 7 of 16 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RNA price targets vary so much?
RNA analyst price targets range from $25 to $25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25 consensus represents the middle ground.